/
EVO
$2.80+$0.00 (+0.00%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$973.2M
355M shares
52-week range
$2.31 – $4.42
23% from low
Exchange
NASDAQ
ADRC
Borrow rate
10.77%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-19.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $375.4M | $446.4M | $500.9M | $618.0M | $751.4M | $781.4M | $797.0M | $757.3M |
| Cost of revenue | $263.4M | $313.5M | $375.2M | $466.5M | $577.4M | $606.4M | $682.1M | $694.6M |
| Gross profit | $112.0M | $132.9M | $125.7M | $151.5M | $174.1M | $175.1M | $114.9M | $62.7M |
| Gross margin | 29.8% | 29.8% | 25.1% | 24.5% | 23.2% | 22.4% | 14.4% | 8.3% |
| R&D | $35.6M | $58.4M | $59.6M | $65.7M | $76.6M | $68.5M | $50.9M | $74.3M |
| Operating income | $77.5M | $62.6M | $48.6M | $41.0M | $20.9M | −$47.5M | −$142.5M | −$135.3M |
| EBITDA | $105.9M | $86.8M | $90.4M | $316.6M | −$57.6M | $24.1M | −$80.7M | −$13.9M |
| Net income | $84.2M | $38.2M | $6.3M | $215.5M | −$175.7M | −$83.9M | −$196.1M | −$99.4M |
| Net margin | 22.4% | 8.5% | 1.3% | 34.9% | -23.4% | -10.7% | -24.6% | -13.1% |
| EPS (diluted) | 0.28 | 0.13 | 0.02 | 0.65 | -0.49 | -0.23 | -0.56 | -0.28 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $750M | $-0.36 | $-0.60–$-0.12 | 2 |
| 2027 | $823M | $-0.06 | $-0.16–$0.05 | 2 |
| 2028 | $921M | $0.13 | $0.12–$0.13 | 1 |
| 2029 | $982M | $0.24 | $0.23–$0.25 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Evotec SE American Depositary Shares
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
www.evotec.com- Employees
- 4,553
- IPO / List date
- Jun 2, 1999
Held by traders on TradeandTell
No one on the platform currently holds EVO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in EVO as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EVO yet.
